【24h】

A Review Of Postherpetic Neuralgia

机译:带状疱疹后神经痛的综述

获取原文
       

摘要

Postherpetic neuralgia is one of the most feared complications of herpes zoster and one of the most painful conditions seen in pain practice. Both conditions occur much more commonly in elderly patients and immunosuppressed individuals, and stress may be an important instigator of both conditions. Early treatment of herpes zoster may however reduce the incidence of postherpetic neuralgia. Different clinical patterns of postherpetic neuralgia implying different underlying pain mechanisms, may explain the variation in response to treatment but may also lead to more logical choices in management. Acute Herpes Zoster Infection Herpes zoster (also known as shingles) is the clinical condition of the reactivation of a latent infection with varicella zoster virus usually contracted after an episode of chickenpox in childhood [1]. The virus tends to be reactivated only once in a lifetime, with the incidence of second attacks being less than 5% [1]. The connection between chickenpox and zoster was first suggested in 1892 by a Viennese physician, Janos Von Bokay, after observing several cases of chickenpox in persons exposed to zoster through household contact [2].Herpes zoster most commonly affects a single dermatome, is frequently preceded by pain (preherpetic neuralgia) and is defined by the characteristic unilateral vesicular rash confined to that dermatome [3]. Prevalence of the condition is high, with an estimated 500,000 people per year suffering reactivation of the virus in the USA. Whereas the incidence in immunocompetent patients ranges from 1.2 to 3.4 per 1000 patient years, the incidence in the elderly is considerably higher, ranging from 3.9 to 11.8 per 1000 patient years [3]. This is because T cell immunity to the virus wanes in later life making advanced age the most significant risk factor for the occurrence of reactivated herpes zoster [1]. An additional major risk factor for herpes zoster reactivation is T cell immunosuppression as might occur in conditions such as human immunodeficiency virus (HIV) infection, certain cancers, and immunosuppression treatment after organ transplantation[1,3]. The rash and pain associated with shingles can be both dramatic and severe but in most cases the episode is transient lasting between 2 and 4 weeks [4]. Painful Complications And Their Prevention Although there are several serious complications of zoster (ophthalmic, splanchnic, cerebral, motor), the most common and feared in immunocompetent adults is postherpetic neuralgia (PHN). Its definition is controversial but recent data support the distinction between acute herpetic neuralgia (within 30 days of rash onset), subacute herpetic neuralgia (30-120 days after rash onset), and postherpetic neuralgia (defined as pain lasting at least 120 days from rash onset) [3]. However as PHN may arise at any time after the resolution of acute herpes zoster, a clinically useful definition of PHN is recurrent or persistent localized pain arising or persisting in areas affected by herpes zoster at least 3 months after healing of the skin lesion [5]. The most well established risk factors for PHN are older age, greater severity of acute herpetic neuralgia, more severe rash, and preherpetic neuralgia. Patients with all of these risk factors may have as much as a 50-75% risk of developing PHN [6]. As with other herpes virus infections, psychological distress and stressful life events appear to play an important role in instigating the onset of shingles as well as the development of PHN [3].In treating the acute phase of herpes zoster, apart from keeping the patient comfortable, an attempt must be made to prevent the development of PHN. The mainstay of acute herpes zoster treatment is oral antiviral therapy and the most commonly used drugs are acyclovir, famciclovir, and valacyclovir. All of these agents have been shown to promote resolution of skin lesions and reduce the duration of viral shedding and pain [5,7]. Studies have indicated that antiviral
机译:带状疱疹后神经痛是带状疱疹最令人担忧的并发症之一,也是疼痛实践中最痛苦的病症之一。两种情况在老年患者和免疫抑制的个体中更常见,压力可能是这两种情况的重要诱因。带状疱疹的早期治疗可能会减少带状疱疹后神经痛的发生。带状疱疹后神经痛的不同临床模式暗示了不同的潜在疼痛机制,可能解释了对治疗反应的差异,但也可能导致管理方面更多的逻辑选择。急性带状疱疹感染带状疱疹(也称为带状疱疹)是水痘带状疱疹病毒潜伏感染恢复激活的临床病状,通常在儿童期水痘发作后收缩[1]。该病毒一生往往仅被激活一次,其第二次攻击的发生率不到5%[1]。水痘和带状疱疹之间的联系是由维也纳医师Janos Von Bokay于1892年首次提出的,在观察到几例通过家庭接触而暴露于带状疱疹的人中出现水痘之后[2]。带状疱疹最常影响单个皮肤刀。由疼痛(带状疱疹前神经痛)引起,并由局限于该皮肤刀的特征性单侧水疱疹定义[3]。该病的患病率很高,在美国估计每年有500,000人遭受病毒的再激活。免疫能力强的患者的发病率范围为每1000患者年1.2至3.4,而老年人的发病率则更高,每1000患者年范围为3.9至11.8 [3]。这是因为T细胞对病毒的免疫力在以后的生命中逐渐减弱,从而使高龄成为发生再活化带状疱疹的最重要危险因素[1]。带状疱疹再激活的另一个主要危险因素是T细胞免疫抑制,例如在人体免疫缺陷病毒(HIV)感染,某些癌症以及器官移植后的免疫抑制治疗等情况下可能会发生[1,3]。带状疱疹引起的皮疹和疼痛可能既严重又严重,但在大多数情况下,发作是短暂的,持续2-4周[4]。痛苦的并发症及其预防方法尽管带状疱疹有几种严重的并发症(眼科,内脏,脑,运动),但在有免疫能力的成年人中最常见和最担心的是带状疱疹后神经痛(PHN)。其定义尚有争议,但最新数据支持区分急性疱疹性神经痛(皮疹发作后30天内),亚急性疱疹性神经痛(皮疹发作后30-120天)和疱疹后神经痛(定义为从皮疹持续至少120天的疼痛)发作)[3]。但是,由于在急性带状疱疹消退后的任何时间都可能出现PHN,因此PHN的临床有用定义是在皮肤病变愈合后至少3个月内,在受带状疱疹影响的区域反复出现或持续出现局部疼痛[5]。 。 PHN的最确定的危险因素是年龄更大,急性疱疹性神经痛的严重程度,皮疹和疱疹前神经痛的严重程度更高。具有所有这些危险因素的患者发生PHN的风险可能高达50-75%[6]。与其他疱疹病毒感染一样,心理困扰和压力性生活事件似乎在促使带状疱疹发作和PHN的发展中起着重要作用[3]。在治疗带状疱疹的急性期中,除了保持患者的生存能力外舒适,必须尝试防止PHN的发展。急性带状疱疹治疗的主要方法是口服抗病毒治疗,最常用的药物是阿昔洛韦,泛昔洛韦和伐昔洛韦。所有这些药物已被证明可以促进皮肤病变的消退并减少病毒脱落和疼痛的持续时间[5,7]。研究表明抗病毒药

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号